No Data
No Data
Jiangzhong Pharmaceutical 2024 Annual Results Express Announcement
CHINARES PHARMA (03320): Jiangzhong Pharmaceutical's annual net income attributable to shareholders is 0.785 billion yuan, an increase of 9.22% year-on-year.
CHINARES PHARMA (03320) announced that as of the year ending December 31, 2024, Jiangzhong Pharmaceutical achieved operating...
Jiangzhong Pharmaceutical Reports Strong Profit Growth in 2024
Jiang Zhong Pharmaceutical Co.,Ltd's (SHSE:600750) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Jiangzhong Pharmaceutical (600750.SH): The controlling Shareholder has obtained a commitment letter for a special loan for Shareholding in Stocks.
On December 10, Gelonghui reported that Jiangzhong Pharmaceutical (600750.SH) announced that on December 9, 2024, it received a notice from its controlling shareholder China Resources Jiangzhong Pharmaceutical Group Co., Ltd. (hereinafter referred to as "China Resources Jiangzhong"). China Resources Jiangzhong has recently obtained a loan commitment letter issued by the Nanchang Donghu Branch of the Industrial And Commercial Bank Of China (hereinafter referred to as "ICBC Nanchang Donghu Branch"). ICBC Nanchang Donghu Branch intends to provide a loan limit of no more than 0.084 billion yuan to China Resources Jiangzhong for its shareholding increase plan, with a loan term of 12 months.
China Resources Pharmaceutical Group's Unit Posts Higher Profit in January-September